Active's MAA for multiple sclerosis drug receives EMA acceptance for review

September 2012
PharmaWatch: CNS;Sep2012, Vol. 11 Issue 9, p10
Market Research Report
The article reports on the announcement made by Active Biotech regarding the completion by the European Medicines Agency (EMA) of the marketing authorization application (MAA) validation process and acceptance for review of laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS). Laquinimod is an oral central nervous system (CNS)-active immunomodulator with a novel mechanism of action being developed for MS treatment.


Related Articles

  • Oral Laquinimod for Multiple Sclerosis Treatment Significantly Reduced Disease Activity and Disability Progression While Providing Good Safety and Tolerability.  // Biomedical Market Newsletter;5/14/2011, p467 

    The article reports that Teva Pharmaceutical Industries Ltd. and Active Biotech AB have announced the results from the two-year Phase III ALLEGRO study of laquinimod, an immunomodulator for the treatment of relapsing forms of multiple sclerosis (MS). The data from the study will be presented at...

  • Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Sørensen, Per Soelberg; Bertolotto, Antonio; Edan, Gilles; Giovannoni, Gavin; Gold, Ralf; Havrdova, Eva; Kappos, Ludwig; Kieseier, Bernd C; Montalban, Xavier; Olsson, Tomas // Multiple Sclerosis Journal;Feb2012, Vol. 18 Issue 2, p143 

    Natalizumab is a highly effective immunomodulator in the treatment of multiple sclerosis (MS). Treatment with natalizumab has been associated with progressive multifocal leukoencephalopathy (PML), an infection of the central nervous system (CNS) caused by a pathogenic form of the normally benign...

  • Betaferon.  // Royal Society of Medicine: Medicines;2002, p111 

    The article presents information on Betaferon, a proprietary, prescription-only preparation drug of the immunomodulator interferon. This drug can be used to treat relapsing-remitting multiple sclerosis, and is available in a form for injection.

  • glatiramer acetate.  // Royal Society of Medicine: Medicines;2002, p268 

    The article provides information on the drug glatiramer acetate. It is a recently introduced immunomodulator drug comprised of synthetic polypeptides. It has been used for the reduction of frequency of relapses in ambulatory patients with relapsing-remitting multiple sclerosis. It is...

  • Estudio fase II de tratamiento de pacientes con esclerosis múltiple exacerbante-remitente con biomodulina T. Gámez Morales, Lorenzo Antonio; Lara Rodríguez, Rosa F.; Rodríguez Martín, Román; González-Quevedo Monteagudo, Alina; Fernández Carriera, Rebeca; Marzoa Silva, Natalia // Revista Mexicana de Neurociencia;ene/feb2007, Vol. 8 Issue 1, p28 

    Introducción: La esclerosis múltiple sigue siendo una entidad neurológica de etiología desconocida. En el presente trabajo mostramos los resultados obtenidos con el uso parenteral de la biomodulina T (extracto tfmico cubano de origin bovino), con efectos inmunomodulador y...

  • Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice. Lanzillo, R.; Bonavita, S.; Quarantelli, M.; Vacca, G.; Lus, G.; Amato, L.; Carotenuto, A.; Tedeschi, G.; Orefice, G.; Brescia Morra, V. // Neurological Sciences;Apr2013, Vol. 34 Issue 4, p521 

    Natalizumab is one option for multiple sclerosis patients responding poorly to classical immunomodulators, but pilot studies did not point to its effectiveness as a second-line therapy. Aim of this study was to assess the efficacy of natalizumab as second-line therapy in patients switching from...

  • Other News To Note.  // BioWorld International;7/25/2012, Vol. 17 Issue 30, p5 

    This section offers news briefs on the pharmaceutical industry. Active Biotech of Lund, Sweden said that the European Medicines Agency has finished the validation process for the marketing authorization application for laquinimod in relapsing remitting multiple sclerosis. Celgene International...

  • Síntesis intratecal de IgGy permeabilidad de la barrera sangre-LCR en el seguimiento de pacientes con esclerosis múltiple tratados con biomodulina T. González-Quevedo Monteagudo, Alina; Alfaro Capdegelle, Ileana; Gámez Morales, Lorenzo Antonio; Fernández Carriera, Rebeca; Lara Rodríguez, Rosa F.; Rodríguez Martín, Román; Maza, Julia // Revista Mexicana de Neurociencia;ene/feb2007, Vol. 8 Issue 1, p18 

    Introduction: Multiple sclerosis (MS) has been treated with various immunomodulatory drugs, among which products derived from the thymus have been considered. In the present work the results of an open, controlled clinical trial, where the efficacy of biomoduline T (BT) on the clinical course of...

  • Discontinuation of higher laquinimod doses in two MS trials.  // Reactions Weekly;1/16/2016, Vol. 1584 Issue 1, p1 

    An abstract is presented of the article "Teva and Active Biotech Announce Discontinuation of Higher Doses of Laquinimod in Two Multiple Sclerosis Trials" published on January 4, 2016 on the website www.tevapharm.com.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics